The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

How will the Trump administration's cuts to HIV research impact the progress that's been made towards ending the epidemic in the U.S.?

USAID has been present in Uganda for over sixty years. It has funded development in agriculture, education and research in ...

A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...

USAID has been present in Uganda for over sixty years. It has funded development in agriculture, education and research in ...

UGANDA: UGANDA’S total number of people living with HIV has surpassed 1.5 million, according to the latest 2024 estimates ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting ...